Published

What happened

Shares of several top COVID-19 vaccine makers were sinking on Tuesday. Pfizer (NYSE: PFE) stock was down 2.7% as of 11:09 a.m. EDT. Shares of Pfizers partner, BioNTech (NASDAQ: BNTX), were falling 7%. Moderna (NASDAQ: MRNA) stock was tumbling 5.4%. Novavax (NASDAQ: NVAX) was the biggest loser with its shares declining 8.1%.

Why did these vaccine stocks slump? It wasnt because of any bad news related to COVID-19 vaccines. None of the companies issued press releases that would explain the declines. Instead, were probably just seeing downward pressure on prices as investors take some profits off the table after a nice jump for each of the stocks on Monday following the U.S. Food and Drug Administration full approval of the Pfizer-BioNTech vaccine.

A

Image source: Getty Images.

So what

Its really not all that surprising that these stocks would give up much of the gains from Monday. FDA approval for the Pfizer-BioNTech vaccine was fully expected.

Also, the approval doesnt impact Pfizer or BioNTech financially over the short term. The U.S. had already ordered 500 million doses of the companies COVID-19 vaccine, Comirnaty, plus another 500 million doses to donate to other countries.

If Pfizer and BioNTech didnt receive any near-term material benefits from the full FDA approval, the other vaccine makers certainly didnt either. Moderna hasnt won full FDA approval of its COVID-19 vaccine yet, although its practically a slam dunk that the approval will be on the way. Novavax hasnt even submitted for U.S. Emergency Use Authorization of its COVID-19 vaccine candidate yet.

Now what

Pfizer, BioNTech, and Moderna hope to win EUAs for their vaccines in younger children within the next few months. The companies also will pursue full FDA approvals in these age groups. Novavax plans to file for EUA of its COVID-19 vaccine in the fourth quarter, with submissions in the U.K. and Europe coming even sooner.

Perhaps the most important thing to watch with all of these stocks is the supply deals they secure for 2022 and beyond. All four companies have already signed some supply agreements for delivery beginning next year.

10 stocks we like better than Pfizer
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

They just revealed what they believe are the ten best stocks for investors to buy right now... and Pfizer wasnt one of them! Thats right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of August 9, 2021

Keith Speights owns shares of Pfizer. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

PFE NVAX MRNA BNTX

The Motley Fool

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the worlds greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The companys name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Learn More

Most Popular

Contact us

Find us at the office

Trailor- Verkamp street no. 63, 81415 Zagreb, Croatia

Give us a ring

Dezha Manci
+38 695 645 231
Mon - Fri, 8:00-22:00

Reach out